^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + takinib (EDHS-206) (TAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma
Excerpt:
...we demonstrate that combining trametinib with the TAK1 inhibitor, takinib, is a far more efficient treatment than trametinib alone in NRAS‐mutant melanoma cells.
DOI:
10.1111/pcmr.12825
